RecruitingNot ApplicableNCT07384013
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Sponsor
Rambam Health Care Campus
Enrollment
30 participants
Start Date
Nov 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called metamizole and a drug called metamizole for people with coagulation defect, oncologic diseases, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGmetamizole
chronic metamizole use
DRUGmetamizole
New metamizole users
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07384013
Related Trials
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery
NCT074327111 location
Neural Sensitisation and Neuropsychological Alterations in Painful Chronic Pancreatitis
NCT077076091 location
R.E.C.K vs Exparel in Robotic Nephrectomy
NCT070925661 location
The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair
NCT070760691 location
Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain
NCT075624121 location